"Obesity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Descriptor ID |
D009765
|
| MeSH Number(s) |
C18.654.726.500 C23.888.144.699.500 E01.370.600.115.100.160.120.699.500 G07.100.100.160.120.699.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Obesity".
Below are MeSH descriptors whose meaning is more specific than "Obesity".
This graph shows the total number of publications written about "Obesity" by people in this website by year, and whether "Obesity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 3 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 4 | 2 | 6 |
| 2008 | 3 | 2 | 5 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 1 | 4 |
| 2011 | 7 | 4 | 11 |
| 2012 | 4 | 3 | 7 |
| 2013 | 10 | 7 | 17 |
| 2014 | 9 | 2 | 11 |
| 2015 | 9 | 5 | 14 |
| 2016 | 5 | 6 | 11 |
| 2017 | 5 | 4 | 9 |
| 2018 | 7 | 6 | 13 |
| 2019 | 3 | 3 | 6 |
| 2020 | 5 | 3 | 8 |
| 2021 | 5 | 6 | 11 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 2 | 4 |
| 2025 | 5 | 3 | 8 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Obesity" by people in Profiles.
-
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention. Eur Heart J. 2026 Jun 02; 47(21):2584-2605.
-
Evidence-Based Positioning of Sodium-Glucose Co-transporter?2 Inhibitors and Glucagon-Like Peptide?1 Receptor Agonists in the Management of Chronic Kidney Disease with Type?2 Diabetes and Overweight or Obesity: A Systematic Literature Review. Adv Ther. 2026 May; 43(5):1983-2000.
-
Addressing Primary Care Needs in People Living With Sickle Cell Disease : A Narrative Review. Ann Intern Med. 2026 Mar; 179(3):394-401.
-
Electronic Cigarette Exposure Induces Adverse Cellular Alterations in Skeletal Muscle in Male Mice Subjected to a High-Fat Diet. Int J Mol Sci. 2025 11 27; 26(23).
-
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 06; 406(10520):2631-2643.
-
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. Science. 2025 Oct 09; 390(6769):eadt4169.
-
Racial Disparities in Nocturia Persist Regardless of BMI Among American Women. Urogynecology (Phila). 2025 Aug 01; 31(8):799-806.
-
Push count: a novel and quantitative approach to assessing second-stage labor progress in obese and non-obese patients. J Matern Fetal Neonatal Med. 2025 Dec; 38(1):2529438.
-
Imbalance of ?3 and ?6 Fatty Acids in Breast Milk of Overweight/Obese Women. Nutrients. 2025 Jun 28; 17(13).
-
Great Debates: Undergoing the Knife versus Pill-Popping-The Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity. Am Surg. 2025 Oct; 91(10):1587-1593.